Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?

Earlier this year, ResMed reported quarterly results showing revenue of US$1.46 billion, up 8.6% year on year, with adjusted earnings per share ahead of expectations but accompanied by operating margin pressure from higher R&D and supply chain costs. Although the wider patient monitoring sector generally outperformed expectations, ResMed delivered the weakest revenue surprise and slowest growth among peers, raising questions about how rising expenses could affect its profitability...